IGM Biosciences
IGMS
IGMS was delisted on the 13th of August, 2025.
87 hedge funds and large institutions have $220M invested in IGM Biosciences in 2024 Q1 according to their latest regulatory filings, with 26 funds opening new positions, 22 increasing their positions, 22 reducing their positions, and 11 closing their positions.
136% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 11
118% more call options, than puts
Call options by funds: $107K | Put options by funds: $49K
21% more capital invested
Capital invested by funds: $182M → $220M (+$38.2M)
21% more funds holding
Funds holding: 72 → 87 (+15)
1.95% more ownership
Funds ownership: 66.61% → 68.57% (+2%)
0% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 22
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$7.28M |
| 2 |
Millennium Management
New York
|
+$5.19M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
+$4.6M |
| 4 |
Goldman Sachs
New York
|
+$2.76M |
| 5 |
RG
Redmile Group
San Francisco,
California
|
+$1.17M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$4.42M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$3.32M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$2.3M |
| 4 |
EAM
Exome Asset Management
New York
|
-$1.13M |
| 5 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$1.03M |
IGMS Hedge Fund Activity: Q1 2024 in Review
87 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in IGM Biosciences (IGMS) for Q1 2024, worth a combined $220M — up 21% from $182M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new IGMS positions and 11 closed out — a net gain of 15 holders — while 22 added to existing stakes and 22 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $7.28M. The largest seller was Fidelity Investments, cutting an estimated $4.42M.
- 87 institutional investors held IGM Biosciences (IGMS) as of Q1 2024, up from 72 in Q4 2023.
- Funds reported $220M of IGM Biosciences stock for Q1 2024, up 21% quarter-over-quarter.
- 26 funds opened new IGM Biosciences positions in Q1 2024 and 11 closed out, a net change of +15 holders.
- The largest IGM Biosciences buyer in Q1 2024 was T. Rowe Price Associates, an estimated $7.28M added.
- The largest IGM Biosciences seller in Q1 2024 was Fidelity Investments, an estimated $4.42M sold.
Based on aggregated 13F filings for Q1 2024.